Romidepsin

Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively[1]. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis[2].

Product Specifications

CAS Number

[128517-07-7]

Product Name Alternative

FK 228; FR 901228; NSC 630176

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Romidepsin.html

Purity

99.98

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C/C=C(NC([C@@H](CSSCC/C=C/[C@@H](O1)CC2=O)NC([C@@H](C(C)C)N2)=O)=O)/C(N[C@@H](C(C)C)C1=O)=O

Molecular Formula

C24H36N4O6S2

Molecular Weight

540.70

Precautions

H302, H315, H319, H335

References & Citations

[1]Furumai R, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002 Sep 1;62 (17) :4916-21.|[2]Sun WJ, et al. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol. 2017 Mar 1;127:90-100.